tetano
Editor, Senior Moderator
Transplantation
. 2022 Oct 29.
doi: 10.1097/TP.0000000000004383. Online ahead of print.
Humoral Response to the Fourth BNT162b2 Vaccination and Link Between the Fourth Dose, Omicron Infection, and Disease Severity in Renal Transplant Recipients
Tammy Hod[SUP] 1 2 3 [/SUP], Aharon Ben-David[SUP] 1 2 3 [/SUP], Eytan Mor[SUP] 1 2 [/SUP], Liraz Olmer[SUP] 4 [/SUP], Rebecca Halperin[SUP] 5 [/SUP], Victoria Indenbaum[SUP] 2 6 [/SUP], Pazit Beckerman[SUP] 1 3 [/SUP], Ram Doolman[SUP] 2 6 [/SUP], Keren Asraf[SUP] 2 7 [/SUP], Nofar Atari[SUP] 6 [/SUP], Ohad Benjamini[SUP] 2 8 [/SUP], Yaniv Lustig[SUP] 2 6 [/SUP], Ehud Grossman[SUP] 2 9 [/SUP], Michal Mandelboim[SUP] 2 6 [/SUP], Galia Rahav[SUP] 2 5 [/SUP]
Affiliations
Abstract
Background: The effectiveness of the fourth BNT162b2 vaccination in reducing the rate and severity of coronavirus disease 2019 (COVID-19) caused by the Omicron variant in renal transplant recipients (RTRs) is unknown.
Methods: Interviews were conducted with 447 RTRs regarding the status and timing of the fourth vaccination, prior vaccinations, and preceding COVID-19 infection. RTRs with polymerase chain reaction-confirmed COVID-19 infection from December 1, 2021, to the end of March 2022 were considered to have been infected with the Omicron variant and were interviewed to determine their disease severity. In a subgroup of 74 RTRs, the humoral response to the fourth dose was analyzed. In 30 RTRs, microneutralization assays were performed to reveal the humoral response to wild-type, Delta, and Omicron variant isolates before and after the fourth dose.
Results: Of 447 RTRs, 144 (32.2%) were infected with the Omicron variant, with 71 (49.3%) of the infected RTRs having received the fourth vaccine dose. RTRs who did not receive the fourth dose before the infection had more serious illness. In a subgroup of 74 RTRs, the fourth dose elicited a positive humoral response in 94.6% (70/74), with a significant increase in geometric mean titer for receptor-binding domain immunoglobulin G and neutralizing antibodies (P < 0.001). The humoral responses to the Omicron variant before and after the fourth dose were significantly lower than the responses to the wild-type and the Delta variants.
Conclusion: Overall, the fourth BNT162b2 dose was effective in reducing the rate and severity of Omicron disease in RTRs, despite the reduced humoral response to the variant.
. 2022 Oct 29.
doi: 10.1097/TP.0000000000004383. Online ahead of print.
Humoral Response to the Fourth BNT162b2 Vaccination and Link Between the Fourth Dose, Omicron Infection, and Disease Severity in Renal Transplant Recipients
Tammy Hod[SUP] 1 2 3 [/SUP], Aharon Ben-David[SUP] 1 2 3 [/SUP], Eytan Mor[SUP] 1 2 [/SUP], Liraz Olmer[SUP] 4 [/SUP], Rebecca Halperin[SUP] 5 [/SUP], Victoria Indenbaum[SUP] 2 6 [/SUP], Pazit Beckerman[SUP] 1 3 [/SUP], Ram Doolman[SUP] 2 6 [/SUP], Keren Asraf[SUP] 2 7 [/SUP], Nofar Atari[SUP] 6 [/SUP], Ohad Benjamini[SUP] 2 8 [/SUP], Yaniv Lustig[SUP] 2 6 [/SUP], Ehud Grossman[SUP] 2 9 [/SUP], Michal Mandelboim[SUP] 2 6 [/SUP], Galia Rahav[SUP] 2 5 [/SUP]
Affiliations
- PMID: 36367927
- DOI: 10.1097/TP.0000000000004383
Abstract
Background: The effectiveness of the fourth BNT162b2 vaccination in reducing the rate and severity of coronavirus disease 2019 (COVID-19) caused by the Omicron variant in renal transplant recipients (RTRs) is unknown.
Methods: Interviews were conducted with 447 RTRs regarding the status and timing of the fourth vaccination, prior vaccinations, and preceding COVID-19 infection. RTRs with polymerase chain reaction-confirmed COVID-19 infection from December 1, 2021, to the end of March 2022 were considered to have been infected with the Omicron variant and were interviewed to determine their disease severity. In a subgroup of 74 RTRs, the humoral response to the fourth dose was analyzed. In 30 RTRs, microneutralization assays were performed to reveal the humoral response to wild-type, Delta, and Omicron variant isolates before and after the fourth dose.
Results: Of 447 RTRs, 144 (32.2%) were infected with the Omicron variant, with 71 (49.3%) of the infected RTRs having received the fourth vaccine dose. RTRs who did not receive the fourth dose before the infection had more serious illness. In a subgroup of 74 RTRs, the fourth dose elicited a positive humoral response in 94.6% (70/74), with a significant increase in geometric mean titer for receptor-binding domain immunoglobulin G and neutralizing antibodies (P < 0.001). The humoral responses to the Omicron variant before and after the fourth dose were significantly lower than the responses to the wild-type and the Delta variants.
Conclusion: Overall, the fourth BNT162b2 dose was effective in reducing the rate and severity of Omicron disease in RTRs, despite the reduced humoral response to the variant.